+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report by Product (Trulicity, Wegovy, Ozempic, Mounjaro), Application (Type 2 Diabetes Mellitus, Obesity), Route Of Administration, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 150 Pages
  • June 2024
  • Region: Global
  • Grand View Research
  • ID: 5982939
Description Jump to:
The global GLP-1 receptor agonist market size is expected to reach USD 173.62 billion by 2030, expanding at a CAGR of 21.65% from 2024 to 2030. The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk, which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period.

Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company entered into a license agreement with Chugai Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai’s proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights.

The companies are currently aiming on geographical expansion for increasing the sales output. Novo Nordisk is expanding its business by investing in the manufacturing unit located in North Carolina. The company holds around 50.0% of the market share of GLP-1 receptor agonists and is expected to dominate the market over the forecast period. Furthermore, in July 2018, Sanofi invested about USD 74.1 million in China for establishing an R&D hub to enhance its global reach.

The companies are also focusing on getting approval for other indications like obesity and major adverse cardiovascular events by authorities like the U.S.FDA, EMEA, and others for the existing products to increase their life cycle. For instance, in January 2020, Novo Nordisk received the U.S. FDA approval for Ozempic for Major Adverse Cardiovascular Events (MACE) in type 2 diabetes patients.

GLP-1 Receptor Agonist Market Report Highlights

  • The ozempic segment dominated the market and accounted for a share of 37.77% in 2023. Ozempic is a brand-name U.S. FDA-approved prescription drug used to treat adults with type 2 diabetes.
  • Zepbound is expected to grow at a significant CAGR from 2024 to 2030. This growth can be attributed to its worldwide approval of a drug and high demand due to its high efficacy and tolerability.
  • The type 2 diabetes mellitus segment dominated the market in 2023 and is expected to grow at a CAGR of 20.14% over the forecast period.
  • The parenteral segment held the largest share in 2023 and is expected to grow at a CAGR of 22.14% from 2024 to 2030.
  • The hospital pharmacies segment held the largest share of 50.64% in 2023. The growth of hospital pharmacies has facilitated the integration of several healthcare components, increased inpatient visits for diabetes and obesity consultations, and improved customer convenience in acquiring GLP-1 medications.
  • North America GLP-1 receptor agonist market accounted for a 76.19% share in 2023. Established brands including liraglutide (Victoza), dulaglutide (Trulicity), exenatide (Byetta/Bydureon), and semaglutide (Ozempic) dominate the GLP-1 receptor agonist market in North America.
  • Asia Pacific GLP-1 receptor agonists market is anticipated to witness the fastest growth in the global market. The region's growing healthcare sector, sizable target population, and high unmet clinical needs are some factors projected to provide significant growth potential.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product and Application Outlook
2.2.2. Route of Administration and Distribution Channel outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. GLP-1 Receptor Agonist Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of chronic diseases such as diabetes and obesity
3.2.1.2. Increasing R&D activities for developing novel therapeutics
3.2.1.3. Formulation advancements of oral GLP-1 receptor agonists
3.2.1.4. Increasing awareness about diagnosis and treatment options for diabetes
3.2.2. Market restraint analysis
3.2.2.1. Product failure
3.2.2.2. Patent expiry of blockbuster drugs during the forecast period
3.3. GLP-1 Receptor Agonist Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Pricing Analysis
3.5. Pipeline Analysis
3.6. Patent Expiry Analysis
Chapter 4. GLP-1 Receptor Agonist Market: Product Estimates & Trend Analysis
4.1. Global GLP-1 Receptor Agonist Market: Product Dashboard
4.2. Global GLP-1 Receptor Agonist Market: Product Movement Analysis
4.3. Ozempic
4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4. Rybelsus
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Trulicity
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Saxenda
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Wegovy
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Victoza
4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Mounjaro
4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Zepbound
4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.11. Others
4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. GLP-1 Receptor Agonist Market: Application Estimates & Trend Analysis
5.1. Global GLP-1 Receptor Agonist Market: Application Dashboard
5.2. Global GLP-1 Receptor Agonist Market: Application Movement Analysis
5.3. Type 2 Diabetes Mellitus
5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4. Obesity
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. GLP-1 Receptor Agonist Market: Route of Administration Estimates & Trend Analysis
6.1. Global GLP-1 Receptor Agonist Market: Route of Administration Dashboard
6.2. Global GLP-1 Receptor Agonist Market: Route of Administration Movement Analysis
6.3. Parenteral
6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Oral
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. GLP-1 Receptor Agonist Market: Distribution Channel Estimates & Trend Analysis
7.1. Global GLP-1 Receptor Agonist Market: Distribution Channel Dashboard
7.2. Global GLP-1 Receptor Agonist Market: Distribution Channel Movement Analysis
7.3. Hospital Pharmacies
7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Retail Pharmacies
7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Online Pharmacies
7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. GLP-1 Receptor Agonist Market: Regional Estimates & Trend Analysis By Product, Application, Route of Administration, and Distribution Channel
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Denmark
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Norway
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Participant Overview
9.3. Financial Overview
9.4. Product Benchmarking
9.5. Company Market Share Analysis, 2023
9.6. Strategy Mapping
9.7. Company Profiles
9.7.1. Eli Lilly and Company.
9.7.1.1. Company overview
9.7.1.2. Financial performance
9.7.1.3. benchmarking
9.7.1.4. Strategic initiatives
9.7.2. Sanofi
9.7.2.1. Company overview
9.7.2.2. Financial performance
9.7.2.3. benchmarking
9.7.2.4. Strategic initiatives
9.7.3. Novo Nordisk A/S
9.7.3.1. Company overview
9.7.3.2. Financial performance
9.7.3.3. benchmarking
9.7.3.4. Strategic initiatives
9.7.4. AstraZeneca.
9.7.4.1. Company overview
9.7.4.2. Financial performance
9.7.4.3. benchmarking
9.7.4.4. Strategic initiatives
List of Tables
Table 1 List of key distributors and channel partners
Table 2 List of key emerging companies’/technology disruptors/innovators
Table 3 North America GLP-1 Receptor Agonist Market, by Country, 2018-2030 (USD Million)
Table 4 North America GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 5 North America GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 6 North America GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 7 North America GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 8 U.S. GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 9 U.S. GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 10 U.S.GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 11 U.S. GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 12 Canada GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 13 Canada GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 14 Canada GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 15 Canada GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 16 Mexico GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 17 Mexico GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 18 Mexico GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 19 Mexico GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 20 Europe GLP-1 Receptor Agonist Market, by Country, 2018-2030 (USD Million)
Table 21 Europe GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 22 Europe GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 23 Europe GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 24 Europe GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 25 Germany GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 26 Germany GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 27 Germany GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 28 Germany GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 29 UK GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 30 UK GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 31 UK GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 32 UK GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 33 France GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 34 France GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 35 France GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 36 France GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 37 Italy GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 38 Italy GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 39 Spain GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 40 Italy GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 41 Spain GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 42 Spain GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 43 Denmark GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 44 Spain GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 45 Denmark GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 46 Denmark GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 47 Denmark GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 48 Denmark GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 49 Sweden GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 50 Sweden GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 51 Sweden GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 52 Sweden GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 53 Norway GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 54 Norway GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 55 Norway GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 56 Norway GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 57 Asia Pacific GLP-1 Receptor Agonist Market, by Country, 2018-2030 (USD Million)
Table 58 Asia Pacific GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 59 Asia Pacific GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 60 Asia Pacific GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 61 Asia Pacific GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 62 Japan GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 63 Japan GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 64 Japan GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 65 Japan GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 66 China GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 67 China GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 68 China GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 69 China GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 70 India GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 71 India GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 72 India GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 73 India GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 74 Australia GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 75 Australia GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 76 Australia GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 77 Australia GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 78 South Korea GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 79 South Korea GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 80 South Korea GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 81 South Korea GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 82 Thailand GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 83 Thailand GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 84 Thailand GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 85 Thailand GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 86 Latin America GLP-1 Receptor Agonist Market, by Country, 2018-2030 (USD Million)
Table 87 Latin America GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 88 Latin America GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 89 Latin America GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 90 Latin America GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 91 Brazil GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 92 Brazil GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 93 Brazil GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 94 Brazil GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 95 Argentina GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 96 Argentina GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 97 Argentina GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 98 Argentina GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 99 MEA GLP-1 Receptor Agonist Market, by Country, 2018-2030 (USD Million)
Table 100 MEA GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 101 MEA GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 102 South Africa GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 103 MEA GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 104 South Africa GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 105 South Africa GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 106 South Africa GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 107 South Africa GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 108 Saudi Arabia GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 109 Saudi Arabia GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 110 Saudi Arabia GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 111 Saudi Arabia GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 112 UAE GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 113 UAE GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 114 UAE GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 115 UAE GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Table 116 Kuwait GLP-1 Receptor Agonist Market, by Product, 2018-2030 (USD Million)
Table 117 Kuwait GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Table 118 Kuwait GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Table 119 Kuwait GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
List of Figures
Figure 1 GLP-1 Receptor Agonist Market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value chain-based sizing & forecasting
Figure 7 QFD modelling for market share assessment
Figure 8 GLP-1 Receptor Agonist Market snapshot (2023)
Figure 9 GLP-1 Receptor Agonist Market: Segment snapshot (2023)
Figure 10 Competitive Insights (2023)
Figure 11 Parent market outlook
Figure 12 Related/ancillary market outlook
Figure 13 GLP-1 Receptor Agonist Market driver impact
Figure 14 GLP-1 Receptor Agonist Market restraint impact
Figure 15 Porter’s Five Forces Analysis
Figure 16 SWOT Analysis, By Factor (Political & legal Economic and technological)
Figure 17 Strategic alliance analysis
Figure 18 Recent developments & impact analysis, by key market participants
Figure 19 Key company market share analysis, 2023
Figure 20 Company market position analysis
Figure 21 Definition and scope, by product
Figure 22 Product market share analysis, 2023 & 2030
Figure 23 Segment dashboard
Figure 24 Global GLP-1 Receptor Agonist Market, by product, 2018-2030 (USD Million)
Figure 25 Ozempic market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 26 Rybelsus market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 27 Trulicity market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 28 Saxenda market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 29 Mounjaro market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 30 Victoza market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 31 Zepbound market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 32 Wegovy market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 33 Other market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 34 Definition and scope, by Application
Figure 35 Application market share analysis, 2023 & 2030
Figure 36 Segment dashboard.
Figure 37 Global GLP-1 Receptor Agonist Market, by Application, 2018-2030 (USD Million)
Figure 38 Type 2 diabetes mellitus market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 39 Obesity market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 40 Definition and scope by route of administration
Figure 41 Route of administration market share analysis, 2023 & 2030
Figure 42 Segment dashboard.
Figure 43 Global GLP-1 Receptor Agonist Market, by Route of Administration, 2018-2030 (USD Million)
Figure 44 Parenteral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 45 Oral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 46 Definition and scope, by distribution channel
Figure 47 Distribution channel market share analysis, 2023 & 2030
Figure 48 Segment dashboard.
Figure 49 Global GLP-1 Receptor Agonist Market, by Distribution Channel, 2018-2030 (USD Million)
Figure 50 Hospital pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 51 Retail pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 52 Online pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 53 North America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 54 U.S. market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 55 Canada market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 56 Mexico market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 57 Europe market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 58 UK market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 59 Germany market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 60 Spain market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 61 France market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 62 Italy market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 63 Sweden market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 64 Denmark market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 65 Norway market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 66 Asia Pacific market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 67 China market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 68 Japan market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 69 India market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 70 Australia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 71 South Korea market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 72 Thailand market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 73 Latin America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 74 Brazil market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 75 Argentina market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 76 Middle East and Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 77 South Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 78 Saudi Arabia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 79 UAE market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Figure 80 Kuwait market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)

Companies Mentioned

  • Eli Lilly and Company.
  • Sanofi
  • Novo Nordisk A/S
  • AstraZeneca.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedJune 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 36.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 173.62 Billion
Compound Annual Growth Rate21.6%
Regions CoveredGlobal
No. of Companies Mentioned4

Related Topics

Related Reports

GLP-1 Receptor Agonist Market by Drug Type, Route of Administration, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

GLP-1 Receptor Agonist Market by Drug Type, Route of Administration, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
GLP-1 Receptor Agonist Global Market Report 2024 - Product Image

GLP-1 Receptor Agonist Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2024 - Product Image

Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2024

  • Clinical Trials
  • 100 Pages
  • Global
From
Parkinson's disease - Pipeline Insight, 2024 - Product Image

Parkinson's disease - Pipeline Insight, 2024

  • Drug Pipelines
  • 230 Pages
  • Global
From
Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating Neurodegenerative Diseases as Metabolic Diseases. International Review of Neurobiology Volume 155 - Product Image

Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating Neurodegenerative Diseases as Metabolic Diseases. International Review of Neurobiology Volume 155

  • Book
  • Global
Copyright © 2002-2024 Research and Markets. All Rights Reserved.